LXRX - Lexicon Pharmaceuticals down 11% after neuralgia candidate misses phase 2 primary endpoint

• Lexicon Pharmaceuticals ( NASDAQ: LXRX ) is down 11% in after-hours trading after a mid-stage trial for postherpetic neuralgia LX9211 failed to meet the primary endpoint .
• Although LX9211 achieved a reduction in average daily pain score 0.80 points greater than with placebo, the difference was not statistically significant.
• However, the company said the results "demonstrated clear evidence of effect."
• In June, results from a phase 2 study of LX9211 in diabetic neuropathy did meet its primary endpoint .

For further details see: